Bárbara Melão, MD, PhD

1.1K posts

Bárbara Melão, MD, PhD banner
Bárbara Melão, MD, PhD

Bárbara Melão, MD, PhD

@bavilima

Urologist; Oncology Department @HAManaus; Former Fellow at @UrologyMSK #ASCO25 COI: https://t.co/NwRW5aQR3p

Bergabung Mart 2011
502 Mengikuti781 Pengikut
Tweet Disematkan
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
So honored to serve as a Featured Voice for #ASCO25 among amazing colleagues ✨ Excited to share the latest data and key takeaways from the meeting @OncBrothers @yekeduz_emre @drenriquegrande @DRBakaloudiMD @realbowtiedoc @ReginaBarCar @crisbergerot @ReneeSaliby @MikeSerzanMD @OncoAlert
ASCO@ASCO

Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25

English
1
4
31
2.1K
Bárbara Melão, MD, PhD me-retweet
OncoAlert
OncoAlert@OncoAlert·
News From Industry: TALAPRO Update in #ProstateCancer Source Businesswire and Pfizer buff.ly/HTeEtmv Pfizer reports the Phase 3 TALAPRO-3 trial showed that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in patients with HRR-mutated metastatic hormone-sensitive prostate cancer, exceeding the target hazard ratio. Benefits were consistent across BRCA and non-BRCA mutations. An interim analysis indicated a strong trend toward improved overall survival. @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin @nataliagandur @acampsmalea @BRicciutiMD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago
OncoAlert tweet media
English
0
12
24
1.8K
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
We are all looking forward to #GU26
OncoAlert@OncoAlert

Dear Colleaguest at #GU26 WELCOME TO San Francisco We Are All @OncoAlert 🚨 @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago

English
0
4
6
484
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
BRCAAway Ph2 Trial #ASCOGU26 Greater benefit with 1L Abi+Olaparib combination @OncoAlert @psalustiano @OncoReporte @gilmorgan @nataliagandur @FernandoOnco @realbowtiedoc @DenizCanGuven1 @BiagioRicciutMD @ElisaAgostinett @dr_yakupergun @yekeduz_emre @lungoncdoc @ElisaAgostinett @to_be_elizabeth @ADesaiMD
Yüksel Ürün@DrYukselUrun

BRCAAway final OS update. Front-line combination mattered. Sequential therapy did not catch up. Phase 2. But a clear signal. Test early. Treat early. #gu26 #cancer #oncology @oncoalert @ASCO @medicalwatchBC @DrChoueiri @yekeduz_emre @neerajaiims @CParkMD @Silke_Gillessen @PGrivasMDPhD @VivekSubbiah @TwoOncDocs @OncBrothers @Larvol @nataliagandur @montypal @crisbergerot @DrDanielHeng @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1 @tompowles1 @BraunMDPhD @uromigos @MattGalsky @apolo_andrea @bavilima @SuyogCancer @ONCOassist @gbanna74 @NazliDizman @MedicalwatchFTW @OncLive @urologysummit @IMG_Oncologists @AmandaBinDC @sarah_c_hopkins @MikeSerzanMD

English
0
9
19
925
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
Great point! We definitely see better now #mHSPC #ASCOGU26 @OncoAlert
Yüksel Ürün@DrYukselUrun

Post-op RT + HT. Benefit mainly when pre-RT PSA >0.5. For most, short-term HT is enough. But at PSA >0.5, many are PSMA PET positive? Old trials. New imaging. Selection is everything. @AmarUKishan @DrSpratticus @piet_ost #gu26 #cancer #oncology @oncoalert @ASCO @medicalwatchBC @DrChoueiri @yekeduz_emre @neerajaiims @CParkMD @Silke_Gillessen @PGrivasMDPhD @VivekSubbiah @TwoOncDocs @OncBrothers @Larvol @nataliagandur @montypal @crisbergerot @DrDanielHeng @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1 @tompowles1 @BraunMDPhD @uromigos @MattGalsky @apolo_andrea @bavilima @SuyogCancer @ONCOassist @gbanna74 @NazliDizman @MedicalwatchFTW @OncLive @urologysummit @IMG_Oncologists @AmandaBinDC @sarah_c_hopkins @MikeSerzanMD

English
0
4
9
684
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
@neerajaiims has consistently delivered meaningful contributions to our oncology community ✨ exactly the kind of leadership ASCO needs
OncoAlert@OncoAlert

Dear Colleagues, A Reminder that the ASCO Elections are OPEN and you can cast your vote Now🗳️UNTIL DEC 8, 2025 👉 asco.org/about-asco/asc… ⭐️The Network would like to Congratulate one of Our Founding Faculty🚨 @neerajaiims 🇺🇸of @HuntsmanCancer & @UUtah on being a candidate for the nominating committee WISHING Neeraj and all of the nominees BEST OF LUCK!

English
0
1
5
900
Bárbara Melão, MD, PhD me-retweet
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga@nataliagandur·
💫🌟FDA Approves IsoPSA® — a new blood-based test to refine biopsy decisions in prostate cancer @OncoAlert @APCCC_Lugano @MedicalwatchHQ IsoPSA (Cleveland Diagnostics) becomes the first structure-based PSA assay approved via PMA, offering more accurate risk assessment for high-grade #ProstateCancer. Key points 👇 🔵 Detects cancer-specific structural variants of the PSA protein 🔵 Indicated for men ≥50 with elevated PSA considering biopsy 🔵 Based on large prospective multicenter study (14 sites, US) 🔵 Aims to reduce unnecessary biopsies — up to 75% currently negative 🔵 Already included in NCCN 2025 & AUA/SUO 2023 guidelines 🔵 Builds on the IsoClear™ protein-structure platform A meaningful step toward precision early detection @genentech @abbvie @ASCO @Movember @urologysummit @UCSFCancer businesswire.com/news/home/2025… #ProstateCancer #EarlyDetection #PrecisionOncology #GUOnc #OncoTwitter
Dra. María Natalia Gandur Quiroga tweet media
Ciudad Autónoma de Buenos Aires, Argentina 🇦🇷 English
1
16
33
4.9K
Bárbara Melão, MD, PhD me-retweet
Uğur Özkerim
Uğur Özkerim@UOzkerim·
👏 Excellent discussion by @bavilima & @dandanmena — exploring Lutetium PSMA, BULLSEYE, and Terbium vs Lutetium insights. All the key questions clinicians should be discussing in PSMA-targeted advanced prostate cancer 💬@OncoAlert
OncoAlert@OncoAlert

Dear Colleagues at #ESMO25 Oncology: Here & Now is BACK ‼️ S2E1 GU Oncology Here they discuss Lutetium PSMA or Deferred ADT Listen Here: youtu.be/FSrJ5iL3F-c?si… Join @bavilima 🇧🇷& @dandanmena 🇲🇽 on this Great Webcast as they discuss #ProstateCancer : ✅Rationale between BULLSEYE🎯 Trial ✅Difference Between Lutetium & Terbium ✅Affinity🆚Toxicity ✅FU of patients with PET and much much more..AVAILABLE NOW!!! @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @yekeduz_emre @DrYukselUrun @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88

English
0
2
5
745
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
#ESMO25 Day 2️⃣ Always the best coverage from @OncoAlert 🚨
OncoAlert@OncoAlert

The OncoAlert🚨Round Up Day Two of #ESMO25 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: OUR TOP 5⃣ PICKS Presented Oct 18, 2025 ⭐️DESTINY Breast 11 (291O) ⭐️DESTINY Breast 5 (LBA 1) ⭐️evERA (LBA 16) ⭐️RAMPART ( LBA93 ) ⭐️KEYNOTE-905 ( LBA2 ) @DrChoueiri @OscarTahuahua @UOzkerim @DrMirallas @to_be_elizabeth @OncologyMarwarD @Erman_Akkus @SuyogCancer @Lucarecco @DrYukselUrun @E_de_Azambuja @GaiaGriguolo @ozdogan_md @MarioBalsaMD @Dr_Oncologista @Dr_ElvinaA @ArmandOrlandi @raffcolo @hoperugo @ElisaAgostinett @ErikaHamilton9 @OncBrothers @BianchiniGP @antgiorda @elmayermd @Dr_Ivanoncologo @LoiSher @matteolambe @tompowles1 @nataliagandur @zapatalaguadomd @dralvaropinto @RKSayyid @_ShankarSiva @TiansterZhang @MathewGWilson @cdanicas @DrRishabhOnco @chavarriagaj @ByMadeleineA @docjavip @Timothee_MD @mirrorsmed @weoncologists @Dr_Aggen @davidmarmolejo @OrozcoBelinchon @JyotiBajpai01

English
0
3
9
1K
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
🚨Oncology: Here & Now🚨 An honor to discuss such important topics with the great @dandanmena from @UroTeragLATAM ✨ @wroclawski_uro @WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala @anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero @davidmuniz @fsabino_onco @jardim_denis @Martin_AngelMD @fedelosco @LauBernalOnc @raymanneh @karima_oualla
OncoAlert@OncoAlert

Dear Colleagues at #ESMO25 Oncology: Here & Now is BACK ‼️ S2E1 GU Oncology 🚨 Listen Here: youtu.be/FSrJ5iL3F-c?si… Join @bavilima 🇧🇷& @dandanmena 🇲🇽 on this Great Webcast as they discuss #ProstateCancer : ✅Rationale between BULLSEYE🎯 Trial ✅Difference Between Lutetium & Terbium ✅Affinity🆚Toxicity ✅FU of patients with PET and much much more..AVAILABLE NOW!!! @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @tompowles1 @BraunMDPhD @cdanicas @brian_rini #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @BenWestphalen @NiuSanford

English
0
8
12
1.2K
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
2026 #OncoAlertColloquium REGISTER: oncoalert.m-pages.com/rnaYzs/the-5th…
OncoAlert@OncoAlert

Dear Colleaguest at #ESMO25 A warm invite to our Flagship Event: REGISTER👉 oncoalert.m-pages.com/rnaYzs/the-5th… OncoAlert, ESGO, ESSO, MASCC, SIOG, and our esteemed faculty invite you to the 2026 #OncoAlertColloquium! Experience the very best in oncology delivered over 7 days, with each day dedicated to a specific tumor type. 🗓 When: First week of February 2026 📋 Registration: Now open for the 6th Annual Colloquium #BreastCancer #LungCancer #GynOnc #Melanoma #ProstateCancer #GastricCancer #BladderCancer #KidneyCancer and more Sign up today, and we’ll send you a reminder as the event approaches. Our 2025 Faculty @hoperugo 🇺🇸 @ErikaHamilton9 🇺🇸 @Silke_Gillessen 🇨🇭 @GillSharlene 🇨🇦 @DrBetofMDPhD 🇺🇸 @CF_PC_OvCaGroup 🇬🇧 @NicoloBizzarri 🇮🇹 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @maryam_lustberg 🇺🇸 @DrSGraff 🇺🇸 @CathyEngMD 🇺🇸 @DrJNaidoo 🇮🇪 @matteolambe 🇮🇹 @UmbertoMalapel1 🇮🇹 @agz_eriksson 🇳🇴 @DrRaulCordoba 🇪🇸 @PGrivasMDPhD 🇺🇸 @ARosen380 🇺🇸 Roberto Salgado 🇧🇪 Declan Murphy 🇦🇺 Renu Eapen 🇦🇺 @VincentWenxinXu 🇺🇸 Fatima Cardoso 🇵🇹 @HenningWillers 🇺🇸 @BenWestphalen 🇩🇪 @E_de_Azambuja 🇧🇪 @kevinpunie 🇧🇪 @EnriqueSoto8 🇺🇸 @NiuSanford 🇺🇸 @CharuAggarwalMD 🇺🇸 @MelissaLoh21 🇺🇸 @KatieKeaneMD 🇺🇸 @Abdallah81MD 🇺🇸 @FernandoOnco 🇧🇷 @nataliagandur 🇦🇷 @rooogerthat 🇵🇭 @AStrojnaMD 🇩🇪 Annamaria Ferrero🇮🇹 Alejandra Martinez🇫🇷🇪🇸 @CoquardRay 🇫🇷 Maaike Oonk🇳🇱 @ChargariC 🇫🇷 Kim Hulscher🇳🇱 @EngageEsgo @TanjaSpanic 🇸🇮 @ElisaAgostinett 🇮🇹 @realbowtiedoc 🇺🇸 @BiagioRicciutMD 🇺🇸 Partners @ESSOnews @ESGO_society @CancerCareMASCC @SIOGorg

Norsk
0
5
6
2K
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
#ESMO25 #KidneyCancer @brian_rini discuss OPTIC Trial 👉 RNAseq-guided therapy in mccRCC @wroclawski_uro @WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala @anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero @davidmuniz @fsabino_onco @jardim_denis @Martin_AngelMD @fedelosco @LauBernalOnc @raymanneh @karima_oualla
OncoAlert@OncoAlert

Dear Colleagues at #ESMO25 An Honor to introduce our Faculty 🚨 @brian_rini Discussing the OPTIC Trial in #KidneyCancer 2591O - Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker presented at ESMO Berlin by @DrScottHaake @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88

English
0
5
7
1.1K
Bárbara Melão, MD, PhD me-retweet
OncoAlert
OncoAlert@OncoAlert·
The #OncoAlert5k 🚨Berlin🇩🇪 HUGE THANKS to all of our Friends We Are ALL OncoAlert 🌐 @DrVilmaPBarcia @benjiwal @vibasilios @marcoscl @sevincballi @SandroCavallero @Gino_K_In_USC @MayanaNavarro @DonjetaZeqa @LouisaHempel @CameliaDeak @CameliaDeak @CathyEngMD @rowela_pfizer @milosicevic @LaurenMachos #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @bmassutis @matteolambe @Icro_Meattini
English
4
16
38
6.1K
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
#BladderCancer #ESMO25 @OncoAlert coverage and @PGrivasMDPhD with the highlights from ✨Keynote 905 ✨DV + Toripalimab ✨IMvigor011 @wroclawski_uro @philippespiess @WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala @anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero @davidmuniz @fsabino_onco @jardim_denis @Martin_AngelMD @fedelosco @LauBernalOnc @raymanneh @karima_oualla
OncoAlert@OncoAlert

Dear Colleagues at #ESMO25 A Great pleasure to Introduce our Faculty Dr. Petros Grivas 🇺🇸 from Fred Hutch who talks to us about all of the Exciting #BladderCancer Science being Presented in Berlin ✅ Keynote 905 ✅ Disitamab vedotin (DV) plus toripalimab ✅ IMvigor011 And much more #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @yekeduz_emre @DrYukselUrun @karima_oualla @giannatempopatr

English
0
7
9
1.5K
Bárbara Melão, MD, PhD
Bárbara Melão, MD, PhD@bavilima·
Great #ESMO25 coverage from this amazing @OncoAlert team🚨 Stay tuned ‼️ @OncoAlert @OncoReporte @gilmorgan @nataliagandur @FernandoOnco @realbowtiedoc @DenizCanGuven1 @BiagioRicciutMD @ElisaAgostinett @dr_yakupergun @yekeduz_emre @lungoncdoc @ElisaAgostinett @to_be_elizabeth @ADesaiMD
OncoAlert@OncoAlert

We are in Berlin for #ESMO25 The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 . We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials. From the podium to your smartphone: direct, no fluff and always relevant. #OncoAlertAF 🇺🇸 @WeOncologists 🇧🇪 @ElisaAgostinett 🇦🇷 @nataliagandur 🇮🇹 @to_be_elizabeth 🇫🇷 @acampsmalea 🇺🇸 @BRicciutiMD 🇯🇵 @HHorinouchi 🇺🇸 @Abdallah81MD 🇧🇷 @bavilima 🇧🇷 @FernandoOnco 🇺🇸 @realbowtiedoc 🇹🇷 @Erman_Akkus 🇮🇹 @Lucarecco 🇮🇹 @GaiaGriguolo 🇷🇸 @JankovicK 🇪🇸 @MarioBalsaMD 🇪🇸 @DrMirallas 🇺🇸 @GIMedOnc 🇹🇷 @UOzkerim 🇮🇳 @DrRishabhOnco 🇲🇽 @ReginaBarCar 🇨🇴 @Onco_Cifu88 Ping Faculty @matteolambe @PGrivasMDPhD @E_de_Azambuja @amerseburger @Icro_Meattini @montypal @crisbergerot @aftimosp

English
0
5
9
1.1K
Bárbara Melão, MD, PhD me-retweet
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga@nataliagandur·
🟠 LBA109 – DISCUS: 3 vs 6 cycles of platinum-based chemotherapy before Avelumab maintenance in advanced urothelial carcinoma 👨‍⚕️ Presented by Dr. Enrique Grande (@drenriquegrande) #ESMO25 @OncoAlert @MedicalwatchHQ ➡️ Phase II DISCUS compared 3 vs 6 cycles of platinum-based chemotherapy (cis/gem or carbo/gem) before Avelumab maintenance in untreated advanced UC. ⚡ N = 267; 133 (3C) vs 134 (6C). ⭐ QoL improved with 3C → +8.5 points (p = 0.016). 💡 OS: 18.9 mo in both arms (HR 1.15; p = 0.56). 👉 PFS: 8.0 vs 9.0 mo (HR 1.05; p = 0.79). ⚠️ Grade 3–4 TRAEs: 11.9% (3C) vs 15.7% (6C). 🔆 Conclusion: Shorter induction (3 cycles) followed by Avelumab maintenance preserves efficacy while improving QoL — supporting treatment de-escalation in advanced UC. @DrChoueiri @MyriamChalabi @myESMO #Berlin 🔗 @montypal @DrDanielHeng @VivekSubbiah @HHammersMD @Uromigos #BladderCancer #Avelumab #DISCUS #GU25 #ESMO25 #Oncology #ClinicalTrials
Dra. María Natalia Gandur Quiroga tweet media
English
1
20
33
6.6K
Bárbara Melão, MD, PhD me-retweet
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga@nataliagandur·
🟠 LBA108 – POTOMAC: Durvalumab + BCG vs BCG alone in BCG-naïve high-risk NMIBC 👩‍⚕️ Presented by Dr. Maria De Santis #ESMO25 @OncoAlert @MedicalwatchHQ ➡️ POTOMAC (Phase III, randomized, open-label, international) evaluated Durvalumab + BCG induction + maintenance (I+M) vs BCG (I+M) alone in BCG-naïve, high-risk NMIBC. ⚡ Median follow-up: 60.7 mo (N = 1018). ⭐ Primary endpoint – DFS: met with 32% risk reduction of recurrence or death → HR 0.68 (95% CI 0.50–0.93; p = 0.015). 💡 24-mo DFS: 86.5% (D+BCG I+M) vs 81.6% (BCG I+M). 👉 Secondary endpoint – D+BCG induction-only arm not significant (HR 1.14). ⚠️ Grade 3/4 TRAEs: 21% (D+BCG I+M) vs 4% (BCG I+M); no treatment-related deaths. 🔆 Take-home: One year of Durvalumab with BCG (I+M) delivers a statistically and clinically meaningful DFS benefit and emerges as a new therapeutic option for BCG-naïve high-risk NMIBC. @DrChoueiri @MyriamChalabi @myESMO #Berlin 🔗 @PGrivasMDPhD @tompowles1 @Silke_Gillessen @drenriquegrande @urotoday #BladderCancer #NMIBC #Durvalumab #POTOMAC #GU25 #ESMO25 #Oncology #ClinicalTrials
Dra. María Natalia Gandur Quiroga tweet media
English
0
11
38
3.4K
Bárbara Melão, MD, PhD me-retweet
Morgan Roupret
Morgan Roupret@MRoupret·
At @myESMO #esmo2025 Berlin, I had the privilege to present the #ALBAN trial (GETUG–AFU 37), an academic phase III study led by @AFUrologie & @GETUG_Unicancer @LaCarine1 together with my outstanding co-PI @y_loriot ,co-investigators @PignotG @champiatMD @PrRomainMATHIEU @ThoSeisen @laconss @UrologieParis and many others across 🇫🇷🇧🇪🇪🇸. Atezolizumab + BCG did not improve EFS vs BCG alone (HR 0.98; 95% CI 0.71–1.36). The result was negative across all subgroups, including CIS. Higher ≥G3 TRAEs were observed in the combination arm. These findings highlight that in localized #BladderCancer, systemic toxicity assessment remains a key endpoint to balance benefit and risk. Proud of this collective academic journey started in 2017 — despite the global BCG shortage and COVID-19 — and now published in @Annals_Oncology 📄 doi.org/10.1016/j.anno… with the financial support of @Roche #NMIBC #ESMO25 #OncoUrology #ClinicalResearch @AFUrologie @afufuro @GETUG_Unicancer #EAUguidelines @Uroweb @AmerUrological @ASCO @Uromigos @tompowles1 @DrChoueiri
Morgan Roupret tweet mediaMorgan Roupret tweet mediaMorgan Roupret tweet mediaMorgan Roupret tweet media
English
7
28
82
10.5K
Bárbara Melão, MD, PhD me-retweet
Uğur Özkerim
Uğur Özkerim@UOzkerim·
💥 The @OncoAlert #GUOncology team has once again delivered an outstanding lineup! 🙌 Excited to discuss these studies live at #ESMO25 Berlin 🇩🇪 From PSMAaddition to RAMPART and KEYNOTE-905, the GU field is stronger than ever. Which one are you most looking forward to? 💬 🌍 Follow the global dream team: #OncoAlertAF 🇺🇸 @WeOncologists 🇧🇪 @ElisaAgostinett 🇦🇷 @nataliagandur 🇮🇹 @to_be_elizabeth 🇫🇷 @acampsmalea 🇺🇸 @BRicciutiMD 🇯🇵 @HHorinouchi 🇺🇸 @Abdallah81MD 🇧🇷 @bavilima 🇧🇷 @FernandoOnco 🇺🇸 @realbowtiedoc 🇹🇷 @Erman_Akkus 🇮🇹 @Lucarecco 🇮🇹 @GaiaGriguolo 🇷🇸 @JankovicK 🇪🇸 @MarioBalsaMD 🇪🇸 @DrMirallas 🇺🇸 @GIMedOnc  🇹🇷 @UOzkerim 🇮🇳 @DrRishabhOnco 🇲🇽 @ReginaBarCar
Uğur Özkerim tweet media
English
0
11
35
2.6K

Jelajahi

@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD